Peptides DB
Research-centric peptide and protocol reference hub
Study 18 of 18Desmopressin literatureJCEM case reports · Case reportHigh-impact journal2023

Pregnancy-unmasked latent autoimmune arginine vasopressin deficiency with anti-rabphilin-3a antibody positivity.

This case suggests that pregnancy may unmask latent autoimmune arginine vasopressin deficiency, highlighting the importance of monitoring for such conditions in pregnant patients.

Read at JCEM case reportsAdd to compare

Where it sits

this study against the rest of the desmopressin corpus
2
Preclinical
12
Observational · this one
0
Open-label
2
Randomised
2
Reviews

Summary and findings

This case report discusses a 37-year-old primigravid female who developed severe polydipsia and polyuria in the third trimester, attributed to latent autoimmune arginine vasopressin deficiency. Desmopressin was used to relieve her symptoms, which recurred six months postpartum. The report highlights the role of anti-rabphilin-3A antibodies and persistent MRI changes in diagnosing the condition.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=12023

Abstract

The authors’ words, as JCEM case reports supplied them

Although pregnancy-associated arginine vasopressin (AVP) disorder is rare, it is often attributed to excessive placental vasopressinase activity. However, vasopressinase-independent mechanisms, including gestational unmasking of latent AVP deficiency (AVP-D), may occur. We report a 37-year-old primigravid female who developed severe polydipsia and polyuria in the third trimester. She had hypotonic polyuria with inappropriately low plasma AVP levels and loss of the posterior pituitary bright spot on T1-weighted magnetic resonance imaging (MRI). AVP-D was suspected; desmopressin promptly relieved her symptoms. Desmopressin became unnecessary immediately following delivery; however, at 6 months postpartum, her polydipsia and polyuria recurred. Anterior pituitary dysfunction subsequently developed. Notably, at 6 months postpartum, the posterior pituitary bright spot on MRI remained absent. Herein, the transient postpartum improvement initially mimicked gestational AVP disorder; however, retrospective testing revealed anti-rabphilin-3A antibody positivity, indicating autoimmune hypophysitis involvement. Persistent MRI abnormalities, postdelivery AVP-D recurrence, and subsequent anterior pituitary dysfunction supported an underlying autoimmune etiology. This case raises the possibility that pregnancy may unmask latent autoimmune AVP-D through a vasopressinase-independent mechanism. In patients who develop AVP-D during pregnancy, anti-rabphilin-3A antibody positivity and persistent loss of the posterior pituitary bright spot on MRI may offer crucial diagnostic clues, supporting the significance of long-term endocrine follow-up.

Background

This paper addresses the rare condition of pregnancy-associated arginine vasopressin disorder, which is typically linked to placental vasopressinase activity. Prior knowledge suggests that latent AVP deficiency may be unmasked during pregnancy, but this study explores vasopressinase-independent mechanisms. Understanding these mechanisms is crucial for diagnosis and management in affected individuals.

Methods

The study reports a case of a 37-year-old female during her third trimester, who experienced severe polydipsia and polyuria. Diagnostic measures included plasma AVP level assessment and MRI imaging of the posterior pituitary. The primary outcome was symptom relief following desmopressin administration.

Results

The patient exhibited hypotonic polyuria with low plasma AVP levels and loss of the posterior pituitary bright spot on MRI. Desmopressin provided immediate symptom relief, but symptoms recurred at 6 months postpartum, coinciding with anterior pituitary dysfunction. The absence of the posterior pituitary bright spot persisted at this time.

Interpretation

This case adds to the understanding of how pregnancy can reveal underlying AVP deficiencies, particularly with autoimmune components. While the findings are intriguing, the effect size and clinical significance are uncertain due to the single-case nature of the report. The presence of anti-rabphilin-3A antibodies suggests an autoimmune etiology, but further research is needed to clarify these associations.

Key findings

  • Severe polydipsia and polyuria developed in the third trimester.
  • Inappropriately low plasma AVP levels were observed.
  • Loss of the posterior pituitary bright spot on T1-weighted MRI.
  • Desmopressin promptly relieved symptoms.
  • At 6 months postpartum, polydipsia and polyuria recurred.
  • Anti-rabphilin-3A antibody positivity was revealed upon retrospective testing.

Limitations

  • Single case report limits generalizability.
  • No quantitative results reported.
  • Long-term follow-up needed for broader implications.
  • Potential confounding factors not fully explored.

Elsewhere in the Desmopressin corpus

BMultifocal intracranial hemorrhage on emergency brain CT in a child with end-stage nephrotic syndrome.Radiology case reports · 2026 · Not reported in abstract.HumanAGinkgo biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis: A randomized controlled trial.Journal of pediatric urology · 2026 · n=398 · Median wet nights per week after 3 months: combination group 0 [IQR 0-2], GBE 6 [0.5-6.5], Desmopressin 2 [0-6], p<0.001.HumanBEvaluation of Ease of Use for Pediatric Medications Requiring Decapsulation, Dissolution, or Partial Dosing: A Questionnaire-Based Study in Japan.Therapeutic innovation & regulatory science · 2026 · n=312 · Not reported in abstract.HumanDVon Willebrand Disease Type 2A: An Update.Seminars in thrombosis and hemostasis · 2026reviewAEfficacy and safety of first-line therapies and first-line-based combination therapies for monosymptomatic nocturnal enuresis in children: a network meta-analysis.Pediatric nephrology (Berlin, Germany) · 2026 · n=2424 · Desmopressin plus oxybutynin, tolterodine, or solifenacin significantly improved CR compared to desmopressin monotherapy.reviewDConsensus Recommendations for the Clinical Management of Wolfram syndrome Using a Delphi Methodbiorxiv-preprint · 2026 · 35 final consensus statements reached ≥80% agreement.review